Every 10-Q that Azenta, Inc. (AZTA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow AZTA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AZTA filings page.
Azenta, Inc. reported third‑quarter 2026 revenue from continuing operations of 161,178 (in thousands), up from 143,855, producing gross profit of 72,356. Higher operating costs led to an operating loss of 4,178 and a loss from continuing operations of 1,529, while discontinued operations contributed income of 3,985, resulting in net income of 2,456.
For the nine months ended June 30, 2026, revenue was 454,615 (in thousands) and a non‑cash goodwill impairment of 149,083 drove a loss from continuing operations of 163,740 and a total net loss of 173,774. Total assets were 1,876,211, including cash and cash equivalents of 189,654 and marketable securities of 332,230, with stockholders’ equity of 1,510,129.
Azenta completed the sale of its B Medical Systems business for $63.0 million, including a $35.0 million secured Vendor Loan Agreement at 6.0% interest, and acquired UK Biocentre for approximately $27.5 million to expand sample management services. It repurchased 2.3 million shares for $50.0 million under a $250.0 million authorization and reduced a legacy semiconductor divestiture loss contingency by $1.8 million after a New York court dismissed Edwards Vacuum LLC’s indemnification lawsuit.
Azenta, Inc. reported quarterly revenue of $144.8 million, roughly flat with the prior year, but recorded a large non‑cash goodwill impairment that pushed results deeply into the red. Operating loss reached $165.8 million, driven by a $149.1 million impairment related to its Multiomics and Sample Management Solutions reporting units.
From continuing operations, Azenta posted a net loss of $157.0 million, compared with a loss of $19.8 million a year earlier, and total net loss was $160.8 million. The B Medical Systems business remains classified as discontinued operations and held for sale; a planned $63.0 million sale to Thelema has been delayed because Thelema has not yet secured financing, although a $9.0 million deposit has been received and the share purchase agreement remains in effect.
Azenta closed the acquisition of UK Biocentre for about $27.5 million net of cash acquired, adding U.K. sample management capabilities and recording $5.1 million of goodwill. The company ended the quarter with $234.0 million in cash and cash equivalents and $324.3 million in marketable securities, providing sizable liquidity despite restructuring costs and ongoing transformation initiatives.
Azenta, Inc. reported a net loss of $15.4M for the quarter ended December 31, 2025, compared with a loss of $11.0M a year earlier. Total revenue from continuing operations was broadly flat at $148.6M, with Sample Management Solutions at $81.4M and Multiomics at $67.2M.
Continuing operations generated a loss of $5.2M, while discontinued operations, mainly the B Medical Systems business, added a further loss of $10.2M. Azenta recorded a $9.7M loss on assets held for sale as it moves toward divesting B Medical.
Under a Share Purchase Agreement signed with Thelema S.À R.L., B Medical Systems is being sold for $63.0M. Thelema has paid a $9.0M deposit, with the remaining $54.0M due on or before March 31, 2026, subject to Thelema obtaining final financing; if this fails, Azenta retains $5.0M as a break-up fee.
Azenta ended the quarter with $336.6M in cash and cash equivalents, plus $228.9M in marketable securities, and total assets of $2.07B against liabilities of $359.6M. The company continues its 2024 restructuring program and has a new $250M share repurchase authorization through December 31, 2028, with no buybacks yet executed.